Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
There remains no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, state the authors of an updated Cochrane Review, which now contains 11 trials across 3409 people.
Health inequalities facing women and girls, already stark before the onset of COVID-19, have widened glaringly during the pandemic. Lockdowns restricted access to sexual and reproductive health services, increased violence against women, and interrupted girls’ education.
Researchers showed that Google search data could be utilized for monitoring the spread of COVID-19 cases.
Not long ago, Kansas showed strong bipartisan support for vaccines as a tool to support a robust public health system.
In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.
Researchers identified drugs inhibiting the entry of SARS-CoV-2.
A recent study published in the New England Journal of Medicine investigated the impact of ivermectin, an antiparasitic drug, as an early treatment option among coronavirus disease 2019 (COVID-19) patients.
Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.
While the vast majority of U.S. adults who are fully vaccinated and boosted against Covid-19 would be likely to recommend vaccinating a 5- to 11-year-old, over a third of fully vaccinated adults who have not had a booster shot have reservations about Covid-19 vaccination for a child that age, according to survey data analysis by the Annenberg Public Policy Center of the University of Pennsylvania.
The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.
Researchers described the changes in viral ribonucleic acid the decline in viral load, and the immune response of SARS-CoV-2-infected patients, in a new preprint study.
Researchers from hospitals around Malaysia have been looking into the efficacy of the controversial drug ivermectin as a possible COVID-19 treatment.
Two treatments that have been shown to be ineffective against COVID-19—hydroxychloroquine and ivermectin—were more heavily prescribed in the latter part of 2020 in U.S. counties with a higher Republican vote share in the 2020 presidential election, according to a new research letter co-authored by researchers from Harvard T.H. Chan School of Public Health.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University has expanded its testing platform to evaluate ivermectin at a higher dose for a longer period of time.
The University of Cincinnati is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.
One dose of an anti-parasite drug was just as effective as two at significantly reducing the spread of scabies, the contagious, intensely itchy skin condition, according to a new study.
In a recent study, whole mRNA-seq was used to investigate the global effects of SARS-CoV-2 viral genes Nsp6, Nsp8, and M on the transcriptome of hPSC-CMs.
In a new study, researchers have been investigating the effects of megadoses of corticosteroids on hospitalized COVID-19 patients.
Antibiotic-resistant bacterial infections resulted in more than 1.2 million deaths worldwide in 2019, exceeding the number caused by HIV/AIDS and malaria, says a study spanning 204 countries and territories.
Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.